Advertisement

Should We Screen High-Risk Populations for NAFLD?

  • Cyrielle CaussyEmail author
Fatty Liver Disease (V Ajmera, Section Editor)
  • 3 Downloads
Part of the following topical collections:
  1. Topical Collection on Fatty Liver Disease

Abstract

Purpose of review

Nonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide and yet remains largely underdiagnosed. However, whether a systematic screening in high-risk population for NAFLD should be performed remains debated.

Recent findings

Over the past decade, a better knowledge of the natural history and epidemiology of NAFLD has identified high-risk population for NAFLD including obese and type 2 diabetes patients. Moreover, the presence of advanced fibrosis has been identified as the major determinant of overall and liver-related mortality. Moreover, several non-invasive biomarkers have been developed for the screening of advanced fibrosis while therapeutic clinical trials are intensive field of research.

Summary

Screening for advanced fibrosis in high-risk population for NAFLD should be performed as it would benefit to the patients. However further studies are needed to determine the optimal strategy and cost-effectiveness of such screening.

Keywords

Obesity Nonalcoholic fatty liver disease Type 2 diabetes Fibrosis Cirrhosis Biomarkers 

Notes

Compliance with Ethical Standards

Conflict of Interest

Cyrielle Caussy is a consultant for Gilead, NovoNordisk, Liponexus, AstraZeneca.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global Perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82.  https://doi.org/10.1002/hep.30251Important article highligthing the importance of the prevalence of NAFLD and expected increase burden. CrossRefPubMedGoogle Scholar
  2. 2.
    •• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.  https://doi.org/10.1002/hep.29367Most recent pratice guideline for the management of NAFLD. CrossRefPubMedGoogle Scholar
  3. 3.
    Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.  https://doi.org/10.1001/jama.2015.5370.CrossRefGoogle Scholar
  4. 4.
    Cheung A, Figueredo C, Rinella ME. Nonalcoholic fatty liver disease: identification and management of high-risk patients. Am J Gastroenterol. 2019;114(4):579–90.  https://doi.org/10.14309/ajg.0000000000000058.CrossRefPubMedGoogle Scholar
  5. 5.
    •• Loomba R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. J Hepatol. 2018;68(2):296–304.  https://doi.org/10.1016/j.jhep.2017.11.028Important review article ot the different non-invasive imaging modalities available for the detection of liver fibrosis. CrossRefPubMedGoogle Scholar
  6. 6.
    •• Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305–15.  https://doi.org/10.1016/j.jhep.2017.11.013Important review article ot the different non-invasive blood-based modalities available for the detection of liver fibrosis. CrossRefPubMedGoogle Scholar
  7. 7.
    Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. J Hepatol. 2018;68(2):362–75.  https://doi.org/10.1016/j.jhep.2017.10.015.CrossRefPubMedGoogle Scholar
  8. 8.
    • Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68(1):361–71.  https://doi.org/10.1002/hep.29724 Most recent review article exposing the current and drug under development for the treatment of NAFLD.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.  https://doi.org/10.1016/j.jhep.2017.07.027.CrossRefPubMedGoogle Scholar
  10. 10.
    Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97 e10.  https://doi.org/10.1053/j.gastro.2015.04.043.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.  https://doi.org/10.1002/hep.27368.CrossRefGoogle Scholar
  12. 12.
    • Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65.  https://doi.org/10.1002/hep.29085Important meta-analysis demonstating the prognostic value of advanced fibrosis in overall and liver-related mortality. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.  https://doi.org/10.1053/j.gastro.2014.11.039.CrossRefPubMedGoogle Scholar
  14. 14.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–95.  https://doi.org/10.1002/hep.26986.CrossRefGoogle Scholar
  15. 15.
    Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420–7.  https://doi.org/10.1053/jhep.2003.50320.CrossRefPubMedGoogle Scholar
  16. 16.
    Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. World Journal of Gastroenterology. 2006;12(13):2080–5.CrossRefGoogle Scholar
  17. 17.
    Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35(6):1485–93.  https://doi.org/10.1053/jhep.2002.33324.CrossRefPubMedGoogle Scholar
  18. 18.
    Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. Journal of Gastroenterology and Hepatology. 2009;24(2):248–54.  https://doi.org/10.1111/j.1440-1746.2008.05640.x.CrossRefPubMedGoogle Scholar
  19. 19.
    Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682–9.  https://doi.org/10.1002/hep.21103.CrossRefPubMedGoogle Scholar
  20. 20.
    Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian journal of gastroenterology. 2009;44(10):1236–43.  https://doi.org/10.1080/00365520903171284.CrossRefPubMedGoogle Scholar
  21. 21.
    Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258–67.  https://doi.org/10.1016/j.atherosclerosis.2013.07.052.CrossRefPubMedGoogle Scholar
  22. 22.
    •• Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600.  https://doi.org/10.1016/j.jhep.2016.05.013Important meta-analysis underlying the assocation between NAFLD and increase risk of cardiovascular disease. CrossRefPubMedGoogle Scholar
  23. 23.
    Harbin WP, Robert NJ, Ferrucci JT Jr. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology. 1980;135(2):273–83.  https://doi.org/10.1148/radiology.135.2.7367613.CrossRefPubMedGoogle Scholar
  24. 24.
    Ito K, Mitchell DG, Hann HW, Kim Y, Fujita T, Okazaki H, et al. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol. 1999;173(3):591–6.  https://doi.org/10.2214/ajr.173.3.10470885.CrossRefPubMedGoogle Scholar
  25. 25.
    Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology. 2008;51(Suppl 1):17–26.  https://doi.org/10.1159/000122595. CrossRefPubMedGoogle Scholar
  26. 26.
    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–90.  https://doi.org/10.1038/nrgastro.2013.171.CrossRefPubMedGoogle Scholar
  27. 27.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.  https://doi.org/10.1111/j.1365-2036.2011.04724.x.CrossRefPubMedGoogle Scholar
  28. 28.
    Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.  https://doi.org/10.1016/j.jhep.2006.06.013.CrossRefPubMedGoogle Scholar
  29. 29.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.  https://doi.org/10.1056/NEJMoa021423.CrossRefPubMedGoogle Scholar
  30. 30.
    Hagstrom H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut. 2018;67(8):1536–42.  https://doi.org/10.1136/gutjnl-2016-313622.CrossRefPubMedGoogle Scholar
  31. 31.
    Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.  https://doi.org/10.1053/j.gastro.2010.09.038.CrossRefPubMedGoogle Scholar
  32. 32.
    Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212–8.  https://doi.org/10.2337/dc06-2247.CrossRefPubMedGoogle Scholar
  33. 33.
    Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, et al. Prevalence and markers of advanced liver disease in type 2 diabetes. QJM. 2012;105(5):425–32.  https://doi.org/10.1093/qjmed/hcr233.CrossRefPubMedGoogle Scholar
  34. 34.
    Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100(6):2231–8.  https://doi.org/10.1210/jc.2015-1966.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700–6.  https://doi.org/10.1111/j.1478-3231.2011.02482.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116(7):539–64.  https://doi.org/10.1042/CS20080253.CrossRefPubMedGoogle Scholar
  37. 37.
    Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43(1):83–95.  https://doi.org/10.1111/apt.13405.CrossRefPubMedGoogle Scholar
  38. 38.
    Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54(3):837–45.  https://doi.org/10.1002/hep.24483.CrossRefPubMedGoogle Scholar
  39. 39.
    Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care. 2016;39(4):632–8.  https://doi.org/10.2337/dc15-1876.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Arab JP, Barrera F, Gallego C, Valderas JP, Uribe S, Tejos C, et al. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. Ann Hepatol. 2016;15(5):721–8.  https://doi.org/10.5604/16652681.1212434. CrossRefPubMedGoogle Scholar
  41. 41.
    Yeung MW, Wong GL, Choi KC, Luk AO, Kwok R, Shu SS, et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. J Hepatol. 2017.  https://doi.org/10.1016/j.jhep.2017.09.020. CrossRefGoogle Scholar
  42. 42.
    • Younossi ZM, Golabi P, de Avila L, Minhui Paik J, Srishord M, Fukui N, et al. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. J Hepatol. 2019.  https://doi.org/10.1016/j.jhep.2019.06.021Recent meta-analysis of the prevalence of NAFLD and NASH in patients with T2DM. CrossRefGoogle Scholar
  43. 43.
    Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–24.  https://doi.org/10.1002/hep.23784.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262–5.CrossRefGoogle Scholar
  45. 45.
    McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55.  https://doi.org/10.1016/j.jhep.2014.11.034.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109–22.  https://doi.org/10.1002/dmrr.1291.CrossRefPubMedGoogle Scholar
  47. 47.
    Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62(1 Suppl):S65–75.  https://doi.org/10.1016/j.jhep.2015.02.041. CrossRefPubMedGoogle Scholar
  48. 48.
    Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713–23.  https://doi.org/10.1002/hep.26672.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab. 2016;101(2):644–52.  https://doi.org/10.1210/jc.2015-3111.CrossRefPubMedGoogle Scholar
  50. 50.
    Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51(3):444–50.  https://doi.org/10.1007/s00125-007-0897-4.CrossRefPubMedGoogle Scholar
  51. 51.
    Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5(12):2166–71.  https://doi.org/10.2215/CJN.05050610.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Li Y, Zhu S, Li B, Shao X, Liu X, Liu A, et al. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol. 2014;46(9):1785–91.  https://doi.org/10.1007/s11255-014-0796-9.CrossRefPubMedGoogle Scholar
  53. 53.
    Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.  https://doi.org/10.1038/nrgastro.2013.41.CrossRefPubMedGoogle Scholar
  54. 54.
    Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114.  https://doi.org/10.1038/nrendo.2017.173.CrossRefPubMedGoogle Scholar
  55. 55.
    Cui J, Chen CH, Lo MT, Schork N, Bettencourt R, Gonzalez MP, et al. Shared genetic effects between hepatic steatosis and fibrosis: a prospective twin study. Hepatology. 2016;64(5):1547–58.  https://doi.org/10.1002/hep.28674.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology. 2015;149(7):1784–93.  https://doi.org/10.1053/j.gastro.2015.08.011.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(9):1162–9.  https://doi.org/10.1016/j.cgh.2006.06.001.CrossRefPubMedGoogle Scholar
  58. 58.
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96(10):2957–61.  https://doi.org/10.1111/j.1572-0241.2001.04667.x.CrossRefPubMedGoogle Scholar
  59. 59.
    • Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest. 2017;127(7):2697–704.  https://doi.org/10.1172/JCI93465First prospective study to determine a higher risk of advanced fibrosis among first-degree relatives of patients with NAFLD-cirrhosis. CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    •• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.  https://doi.org/10.1016/j.jhep.2015.11.004Most recent European guidelines that recommend the systematic screening for advanced fibrosis in high-risk population for NAFLD. CrossRefGoogle Scholar
  61. 61.
    •• American Diabetes A. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S34–45.  https://doi.org/10.2337/dc19-S004Most recent practice guideline from American Diabetes Association that recommend the screening for NAFLD in patients with T2DM. CrossRefGoogle Scholar
  62. 62.
    McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–9.  https://doi.org/10.1136/gut.2010.216077.CrossRefPubMedGoogle Scholar
  63. 63.
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.  https://doi.org/10.1002/hep.21496.CrossRefPubMedGoogle Scholar
  64. 64.
    Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47(2):455–60.  https://doi.org/10.1002/hep.21984. CrossRefPubMedGoogle Scholar
  65. 65.
    Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40.  https://doi.org/10.1186/1471-230X-7-40.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50(1):165–73.  https://doi.org/10.1016/j.jhep.2008.07.035.CrossRefPubMedGoogle Scholar
  67. 67.
    Loomba R, Jain A, Diehl AM, Guy CD, Portenier D, Sudan R, et al. Validation of serum test for advanced liver fibrosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2019;17(9):1867–76 e3.  https://doi.org/10.1016/j.cgh.2018.11.004.CrossRefPubMedGoogle Scholar
  68. 68.
    Caussy C, Bhargava M, Villesen IF, Gudmann NS, Leeming DJ, Karsdal MA, et al. Collagen formation assessed by N-terminal propeptide of type 3 procollagen is a heritable trait and is associated with liver fibrosis assessed by magnetic resonance elastography. Hepatology. 2019;70(1):127–41.  https://doi.org/10.1002/hep.30610.CrossRefPubMedGoogle Scholar
  69. 69.
    Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. .  https://doi.org/10.1002/hep.30163.CrossRefGoogle Scholar
  70. 70.
    Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports. 2019.  https://doi.org/10.1016/j.jhepr.2019.06.004.CrossRefGoogle Scholar
  71. 71.
    Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–7.  https://doi.org/10.1136/gut.2007.146019.CrossRefPubMedGoogle Scholar
  72. 72.
    Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118(6):1117–23.  https://doi.org/10.1016/s0016-5085(00)70364-7.CrossRefPubMedGoogle Scholar
  73. 73.
    Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66(6):1158–65.  https://doi.org/10.1016/j.jhep.2017.01.003.CrossRefPubMedGoogle Scholar
  74. 74.
    Bril F, Millan L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, et al. Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2018;20(7):1702–9.  https://doi.org/10.1111/dom.13285.CrossRefPubMedGoogle Scholar
  75. 75.
    Cassinotto C, Boursier J, de Ledinghen V, Lebigot J, Lapuyade B, Cales P, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63(6):1817–27.  https://doi.org/10.1002/hep.28394.CrossRefPubMedGoogle Scholar
  76. 76.
    Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30.  https://doi.org/10.1053/j.gastro.2019.01.042.CrossRefPubMedGoogle Scholar
  77. 77.
    Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156–63 e2.  https://doi.org/10.1016/j.cgh.2018.04.043.CrossRefPubMedGoogle Scholar
  78. 78.
    Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–62.  https://doi.org/10.1002/hep.23312.CrossRefPubMedGoogle Scholar
  79. 79.
    Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology. 2016;63(2):453–61.  https://doi.org/10.1002/hep.28337.CrossRefPubMedGoogle Scholar
  80. 80.
    Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256(2):640–7.  https://doi.org/10.1148/radiol.10091662.CrossRefPubMedGoogle Scholar
  81. 81.
    Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(4):630–7 e8.  https://doi.org/10.1016/j.cgh.2018.05.059.CrossRefPubMedGoogle Scholar
  82. 82.
    Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(3):626–37 e7.  https://doi.org/10.1053/j.gastro.2015.11.048.CrossRefPubMedGoogle Scholar
  83. 83.
    Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607 e2.  https://doi.org/10.1053/j.gastro.2016.10.026.CrossRefPubMedGoogle Scholar
  84. 84.
    Chen J, Yin M, Talwalkar JA, Oudry J, Glaser KJ, Smyrk TC, et al. Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283(2):418–28.  https://doi.org/10.1148/radiol.2016160685.CrossRefPubMedGoogle Scholar
  85. 85.
    Caussy C, Chen J, Alquiraish MH, Cepin S, Nguyen P, Hernandez C, et al. Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs transient elastography in patients with nonalcoholic liver disease. Clin Gastroenterol Hepatol. 2018;16(12):1974–82 e7.  https://doi.org/10.1016/j.cgh.2017.10.037.CrossRefPubMedGoogle Scholar
  86. 86.
    Blond E, Disse E, Cuerq C, Drai J, Valette PJ, Laville M, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? Diabetologia. 2017;60(7):1218–22.  https://doi.org/10.1007/s00125-017-4264-9.CrossRefPubMedGoogle Scholar
  87. 87.
    Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes. Diabet Med. 2017.  https://doi.org/10.1111/dme.13565. CrossRefGoogle Scholar
  88. 88.
    •• Younossi Z, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. GS-06-Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. Journal of Hepatology. 2019;70(1):e5.  https://doi.org/10.1016/S0618-8278(19)30006-4Interim analysis of the first phase 3 clinical trial for the treatment of NASH with positive results presented in International Liver Congress in Vienna 2019. CrossRefGoogle Scholar
  89. 89.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.  https://doi.org/10.1056/NEJMoa0907929.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Kowdley K, Wilson LA, Van Natta ML, Pai RK, Sanyal AJ. Efficacy and safety of vitamin E in nonalcoholic steato- hepatitis patients with and without diabetes: Pooled analysis from the PIVENS and FLINT NIDDK NASH CRN Trials. Hepatology. 2015;62(S1):264A.  https://doi.org/10.1002/hep.28183.CrossRefGoogle Scholar
  91. 91.
    • Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.  https://doi.org/10.1016/j.jhep.2017.05.016Important review article of the impact of diet and physical activity for the treatment of NAFLD. CrossRefPubMedGoogle Scholar
  92. 92.
    Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.  https://doi.org/10.1136/gutjnl-2017-313884.CrossRefPubMedGoogle Scholar
  93. 93.
    Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11(9):797–811.  https://doi.org/10.1080/17474124.2017.1355731.CrossRefPubMedGoogle Scholar
  94. 94.
    Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532–40.  https://doi.org/10.1053/j.gastro.2009.04.052.CrossRefPubMedGoogle Scholar
  95. 95.
    Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149(2):379–88; quiz e15-6.  https://doi.org/10.1053/j.gastro.2015.04.014.CrossRefPubMedGoogle Scholar
  96. 96.
    Goh GB, Schauer PR, McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World Journal of Gastroenterology. 2018;24(28):3112–9.  https://doi.org/10.3748/wjg.v24.i28.3112.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    • Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U. S. claims database. Hepatology. 2018;68(6):2230–8.  https://doi.org/10.1002/hep.30094Important recent study that highlights the high economic burden of NAFLD. CrossRefPubMedGoogle Scholar
  98. 98.
    Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51(3):254–60.  https://doi.org/10.1097/MCG.0000000000000567. CrossRefPubMedGoogle Scholar
  99. 99.
    Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577–86.  https://doi.org/10.1002/hep.28785.CrossRefPubMedGoogle Scholar
  100. 100.
    Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25(11):3282–94.  https://doi.org/10.1007/s00330-015-3731-2.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology. 2017;65(4):1156–64.  https://doi.org/10.1002/hep.28958.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Univ Lyon, CarMen Laboratory, INSERM, INRA, INSA LyonUniversité Claude Bernard Lyon 1Pierre-BéniteFrance
  2. 2.Hospices Civils de Lyon, Département Endocrinologie, Diabète et NutritionHôpital Lyon SudPierre-BéniteFrance

Personalised recommendations